30-Second Takeaway
- Conversion surgery for UR-LAPC yields prolonged survival when preceded by >6 months of effective chemotherapy and favorable preop risk factors.
- Robotic Whipple can match open benchmarks when performed in high-volume centers with low conversion, mortality, and clinically relevant POPF rates.
- Universal ESD for large Barrett’s cancers improves R0 and oncologic control, particularly for T1b lesions, without excess adverse events.
- Treatment choice for early HCC ≤3 cm and converted CRLM should be individualized using recurrence risk, tumor biology, and patient fitness.
- Patient-centered metrics such as DAOH90 and short-term survival prediction models can refine perioperative decisions and institutional benchmarking.
Week ending January 24, 2026
Selection, technique, and systems metrics in contemporary surgical oncology
Four-factor preoperative profile stratifies survival after conversion surgery for UR-LAPC
In 465 patients undergoing conversion surgery for unresectable locally advanced pancreatic cancer after FOLFIRINOX or gemcitabine/nab-paclitaxel, median overall survival reached 43.8 months from treatment start. Preoperative therapy >6.1 months was associated with markedly better overall and recurrence-free survival than shorter treatment. Independent favorable prognostic factors were chemotherapy duration >6 months, FOLFIRINOX-based regimen, normal CA19-9 and CEA, and prognostic nutritional index ≥45. Patients with three or four factors had substantially higher 5-year survival than those with two or fewer, enabling practical preoperative risk stratification.
International benchmarks define acceptable outcomes for robotic Whipple
An international cohort of 418 benchmark robotic Whipple cases from 12 high-volume centers established reference values for safety and quality. Benchmark outcomes included conversion rate ≤4.3%, transfusion ≤2.1%, 6‑month mortality ≤2.2%, and major complications ≤23.2%. Clinically relevant pancreatic fistula and hemorrhage benchmarks were ≤23.6% and ≤12.7%, respectively, with lymph node yield ≥20 for pancreatic ductal adenocarcinoma. Higher center caseload correlated with fewer pancreas-specific complications, while greater technical difficulty increased morbidity, underscoring volume and case selection effects.
ESD-first strategy improves oncologic control for large Barrett’s cancers
In 581 resections of Barrett’s neoplasia (median 20 mm), shifting to an ESD-first strategy for lesions >15 mm increased basal R0 from 69.7% to 91.2%. The greatest R0 improvement occurred in T1b cancers, with basal R0 rising from 33.3% to 81.9%. For T1b lesions, curative resection rates increased and recurrence decreased under the ESD-first approach. ESD achieved higher 2‑year cancer-free survival than EMR, with low and similar adverse event rates between techniques, supporting routine ESD for larger Barrett’s cancers.
Modeling favors esophagectomy over surveillance for long-term outcomes after cCR
A Markov model using SANO trial data compared standard esophagectomy with active surveillance in 60‑year-old patients achieving cCR after neoadjuvant chemoradiation. Over 5 years, esophagectomy yielded higher quality-adjusted life-years and life-years than active surveillance, corresponding to several additional months of benefit. At 2 years, active surveillance slightly improved QALYs, reflecting early quality-of-life advantages without surgery. Sensitivity analyses favored surveillance only when recurrence risk was low, salvageability of recurrence very high, or surgical quality-of-life impact substantial.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.